1. Generics Bulletin
  2. >>Archive

CPTPP deal drops IP increases

Several provisions that would have increased protection for intellectual property (IP) on pharmaceuticals have been omitted from a Comprehensive and Progressive Agreement for a Trans-Pacific Partnership (CPTPP) trade deal agreed by 11 countries on 23 January, and set to be signed on 8 March in Chile. The agreement struck in Tokyo, Japan, between ministers from Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam includes an annex of suspended provisions – several of which cover IP rights for pharmaceuticals – that were included in the draft Trans-Pacific Partnership (TPP) text before the US pulled out of the trade deal last year. These include requirements for data exclusivity of “at least five years” for small molecules and “at least eight years” for biological drugs, as well as patent-term extensions (Generics bulletin, 24 November 2017, page 1). All CPTPP members would have to agree to reinstate such measures for them to apply in future.

Several provisions that would have increased protection for intellectual property (IP) on pharmaceuticals have been omitted from a Comprehensive and Progressive Agreement for a Trans-Pacific Partnership (CPTPP) trade deal agreed by 11 countries on 23 January, and set to be signed on 8 March in Chile. The agreement struck in Tokyo, Japan, between ministers from Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam includes an annex of suspended provisions – several of which cover IP rights for pharmaceuticals – that were included in the draft Trans-Pacific Partnership (TPP) text before the US pulled out of the trade deal last year. These include requirements for data exclusivity of “at least five years” for small molecules and “at least eight years” for biological drugs, as well as patent-term extensions (Generics bulletin, 24 November 2017, page 1). All CPTPP members would have to agree to reinstate such measures for them to apply in future.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

Wockhardt Confirms US Market Exit After Past Challenges

 
• By Adam Zamecnik

Following past challenges on the US market, the Indian pharma player Wockhardt will be shuttering its presence in the country due to commercial reasons.

Biocon Chooses To Settle Over Eylea In US – Will Others Follow?

 
• By Dave Wallace

After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?